Results 81 to 90 of about 7,461 (205)
Screening and prevention of anticoagulant resistance development in house mice: A review [PDF]
Unrestricted use of anticoagulants has resulted in rodents developing resistance to them. This has caused a series of problems regarding reduction in rodent populations, which has further implicated great economic losses and a serious threat to the ...
Blažić Tanja +2 more
doaj
Warfarin Hipersensitivity. How to Deal with it? [PDF]
Os autores descrevem um caso clínico de hipersensibilidade à varfarina traduzido por uma elevação acentuada do INR, aquando da introdução do fármaco em doente com antecedentes tromboembólicos. Da pesquisa de polimorfismos para os genes VKORC1 e CYP2C9,
Borges, A, Lima, AF, Reis, J, Serrano, F
core
ABSTRACT Pharmacogenomics (PGx) is a rapidly evolving field that aims to personalize medicine by identifying genetic variations that influence drug response. While next‐generation sequencing (NGS)–based applications are not yet widely adopted in clinical routine, this study aimed to validate 9 genes of the NGS‐based Ion AmpliSeq Pharmacogenomics Panel ...
Yaowaluck Hongkaew +7 more
wiley +1 more source
Antagoniștii vitaminei K (AVK) sunt utilizați pe scară largă pentru profilaxia primară și secundară a trombembolismului, efectul lor anticoagulant fiind monitorizat prin intermediul INR.
Brudașcă Ioana
doaj +1 more source
Self‐Reported Pharmacogenetic Medication Use in the Our Future Health Cohort
ABSTRACT The aim of this study was to describe self‐reported use of medications with established pharmacogenetic guidance in the Our Future Health (OFH) cohort. We examined four key pharmacogenes—CYP2C19, CYP2C9, CYP2D6, and SLCO1B1—and medications supported by strong evidence for clinical actionability according to the Clinical Pharmacogenetics ...
Padraig Dixon +4 more
wiley +1 more source
ABSTRACT Background The implementation of pharmacogenetics in clinical practice increasingly relies on multigene panels. Objectives The objective of this study is to develop harmonized recommendations for the design and analytical implementation of multigene pharmacogenetic panels, defining clinically relevant genes and associated regions of interest ...
Nicolas Picard +29 more
wiley +1 more source
Characterization of the VKORC1 and CYP2C9 genotypes v2
Vitamin K antagonists are anticoagulants which represent widely prescribed drugs for prevention and treatment of thromboembolic disorders. The molecular target of these drugs is vitamin K epoxide reductase enzyme and their metabolism is performed by the cytochrome P-450 2C9 enzyme, both of which are encoded by polymorphic genes - vitamin K epoxide ...
Mirsada Causevic, Honours BSc, PhD +1 more
openaire +1 more source
High PIVKA‐II expression in HCC correlates with resistance to anti‐PD‐1 plus lenvatinib, driven by an immunosuppressive TME. NQO1/p65/CXCL12 axis recruits Tregs to promote resistance to anti‐PD‐1 plus lenvatinib in HCC with high PIVKA‐II expression.
Biao Gao +18 more
wiley +1 more source
The history and future of pharmacogenetics in Aotearoa/New Zealand
ABSTRACT Pharmacogenetics is the study of genetic variants in genes which may impact on the outcome of drug treatment, either through safety considerations (occurrence of adverse drug reactions or therapeutic failure) or altered drug pharmacokinetics. This paper provides a brief history of pharmacogenetics research in the Aotearoa/New Zealand context ...
Martin A. Kennedy
wiley +1 more source
ABSTRACT Pharmacogenomic (PGx) testing using multi‐gene panels (mgPGx) is documented to improve clinical outcomes; however, real‐world data on its economic impact remain limited. This study aimed to evaluate the utility and economic value of mgPGx testing among Medicare patients within a community‐based health system.
Nihal El Rouby +15 more
wiley +1 more source

